Inovio's Covid-19 vaccine studies just hit a brick wall at the Pentagon. Are other hopefuls in trouble?
Inovio received some harsh news from the Pentagon on Friday regarding its Covid-19 vaccine program, and it could prove foreboding to other mid-stage players in the space.
The US Department of Defense has scuttled funding for Inovio’s Phase III Covid-19 vaccine trial, Inovio said in a press release, but will continue to fund the study’s Phase II segment. Friday’s move comes as a result of a growing availability of authorized vaccines in the US, Inovio said the department communicated to them. Endpoints News has reached out to DoD for comment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.